CTAD24 | Clinical Trials on Alzheimer’s Disease Madrid, Spain | 29 October – 1 November 2024 Be the first to gain access to new data and insights, presented at CTAD24. Access Posters This year at CTAD, we can’t wait to share our latest research with you. There will be four posters, with Michael Spilka, PhD […]
CTAD24 | Clinical Trials on Alzheimer’s Disease Read More »
Revolutionizing Clinical Trial Central Monitoring: Automated Quality Assurance for Faster, Scalable Monitoring by Rachel Newsome, PhD Tuesday 22nd October at 15:45 Accurate administration of rater-based clinical instruments, such as the Clinical Dementia Rating (CDR), is critical for reliable clinical outcomes in Alzheimer’s Disease (AD) trials. However, existing gold-standard quality assurance (QA) processes rely heavily or
Clinical Trials Innovation Summit 2024 Read More »
We caught up with the 2023 CANTAB® Research Grant Winner, Dr Simran Kaur, from the All India Institute of Medical Sciences, New Delhi, India. She shares with us how the grant will help to non-invasively explore the neural underpinnings to establish state and trait markers in neuropsychiatric and neurodegenerative disorders. I, Dr Simran Kaur sincerely
We’re thrilled to have presented our latest research at the ISCTM Autumn Meeting on 12-13 September 2024. Rachel Newsome, PhD shared research into the future of clinical trials with recent validation of AQUA, innovation in cognitive assessments, and cutting-edge methodologies. Download poster If you have any questions or would like to discuss any of our
Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes-002 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK. The Bio-Hermes-002 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims to determine how accurately digital
We’ve joined forces with ESSEXLab at the Centre for Behavioural Science (CBS), University of Essex, to gather normative data from latency-based and rater-scored tasks like our Reaction Time (RTI) task and Verbal Recognition Memory (VRM). This partnership will significantly enrich our normative offerings further and provide robust benchmarks, demonstrating the sensitivity in CANTAB endpoints. Our
Cambridge, UK – 30 April 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessment, has announced that The Michael J. Fox Foundation for Parkinson’s Disease Research will incorporate its CANTAB® cognitive assessments into the Parkinson’s Progression Markers Initiative (PPMI). The landmark initiative will use Cambridge Cognition’s technology to identify the cognitive
by Martina De LilloClinical ScientistCambridge Cognition Disorders of the Central Nervous System (CNS) affect billions of people worldwide (The Lancet Neurology, 2022), representing an important cause of death and disability around the world. Life expectancy has been extended in the last years which has increased the number of brain pathologies related to aging, such as
Cambridge, UK – 23 April 2024: Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that Monument Therapeutics Limited (“Monument”) a precision neuroscience company spun-out from, and partly owned by Cambridge Cognition, has completed a £1.0 million fundraise and announced a further £0.5 million grant
We caught up with the 2023 CANTAB Research Grant Secondary Award Winner, Louise Engelbrecht, who tells us how the grant will help to provide a better understanding of cognitive function during ultra-endurance performance and the role of ketone ester supplements to retain cognitive function. ​ I was elated when I got the news about receiving
